Institute for Immunity, Transplantation and Infection

The Stanford - LPCH Vaccine Program

Historically, vaccines against infectious agents have had a more profound impact on the health of the world's population than any other advance in the biomedical sciences.  Vaccine research is entering an exciting phase of expansion and innovation which is expected to yield many new approaches to disease prevention and therapy that will be useful well beyond the traditional domain of infectious diseases.  For example, novel strategies using vaccines to prevent or treat cancer and allergic diseases are now being developed.  New models and techniques are now available to measure the benefit and cost of vaccination in different populations.  The goal of the Stanford -LPCH Vaccine Program is to ensure that our faculty has the best possible opportunity to make important contributions to progress in this field and to bring the fruits of  this research to people.

The Stanford-LPCH Vaccine Program was established in 1997 with Drs. Ann Arvin and Harry Greenberg as Directors.  Ann Arvin, MD, is professor of Pediatrics, Chief of the Pediatric Infectious Diseases Division and a Director of the Stanford-LPCH Vaccine Program.  Dr. Greenberg is a Professor of Medicine, Senior Associate Dean - Research and Director of the Stanford-LPCH Vaccine Program.  In 1999, Dr. Cornelia Dekker was appointed as the Medical Director for the Stanford-LPCH Vaccine Program to organize the clinical aspects of the program.  In this regard, the Stanford-LPCH Vaccine Program has established the infrastructure to do clinical studies of vaccines in both children and adults.  Collaborations with local medical groups, Vaden Student Health, and community child care centers encouraged enrollment into various clinical trials sponsored by NIH, the CDC and the pharmaceutical industry.

New Clinical Trial:
Immune Senescence in the Elderly:  Comparison of Immune Responses to Influenza Vaccine in Adults of Different Age Groups

 Summary  The Stanford-LPCH Vaccine Program is seeking healthy adults to take part in an influenza vaccine study.   You are invited to participate in a research study of the adaptive immune response to influenza (commonly known as "the flu").  We hope to discover new biological markers that are associated with age-related immune response to the seasonal flu vaccine.  The flu vaccine used in this study is licensed by the FDA and is not experimental. 

 

Thank you for taking the time to learn more about our study. We look forward to the possibility of working with you.  Please feel free to contact us if you have any questions.  

ELIGIBILITY: We are now enrolling healthy adults who are 18 to 30 and 60-100 years of age. To see if you meet the eligibility requirements and to learn more about the visit schedule for this study, please click this link:  Eligibility Criteria and Visit Schedule

FOR MORE INFORMATION:
Please contact the Stanford-LPCH Vaccine Program at (650) 498-7284, or email Vaccines_Program at stanford dot edu [Vaccines_Program] and provide a phone number where we can reach you. (For further information regarding your rights as a participant, please call 1-866-680-2906 or write the Administrative Panel on Human Subjects in Medical Research, Administrative Panels Office, Stanford University, Stanford, CA  94305-5401.)

Stanford Medicine Resources:

Footer Links: